Drug
Odevixibat
Odevixibat is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_3
4
80%
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
4(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(2)
Other(1)
Detailed Status
Completed2
Active, not recruiting1
unknown1
Enrolling by invitation1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 34 (100.0%)
Trials by Status
active_not_recruiting120%
unknown120%
completed240%
enrolling_by_invitation120%
Recent Activity
1 active trials
Showing 5 of 5
unknown
Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis
NCT04483531
completedphase_3
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
NCT04336722
active_not_recruitingphase_3
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
NCT05035030
enrolling_by_invitationphase_3
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
NCT05426733
completedphase_3
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
NCT04674761
Clinical Trials (5)
Showing 5 of 5 trials
NCT04483531
Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis
NCT04336722Phase 3
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
NCT05035030Phase 3
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
NCT05426733Phase 3
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
NCT04674761Phase 3
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5